SEREVENT DISKUS

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

SALMETEROL AS XINAFOATE

متاح من:

GLAXO SMITH KLINE (ISRAEL) LTD

ATC رمز:

R03AC12

الشكل الصيدلاني:

POWDER FOR INHALATION

تركيب:

SALMETEROL AS XINAFOATE 50 MCG

طريقة التعاطي:

INHALATION

نوع الوصفة الطبية :

Required

المصنعة من قبل:

GLAXO WELLCOME PRODUCTION, FRANCE

المجموعة العلاجية:

SALMETEROL

المجال العلاجي:

SALMETEROL

الخصائص العلاجية:

Salmeterol is a selective beta-2-agonist indicated for reversible airways obstruction in patients with asthma and chronic obstructive pulmonary disease (COPD).In asthma (including nocturnal asthma and exercise induced symptoms) it is indicated for those treated with inhaled corticosteroids who require a long-acting beta agonist in accordance with current treatment guidelines.

تاريخ الترخيص:

2020-03-31

نشرة المعلومات

[לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט *
[סגירה]
סגור *
דף הבית [http://www.health.gov.il/] *
אודות *
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx] *
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx] *
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx] *
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx] *
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx] *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3] *
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx] *
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx] *
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx] *
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx] *
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx] *
יחידות המשרד *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx] *
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx] *
נושאים *
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx] *
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/

خصائص المنتج

_Page 1 of 11 _
SEREVENT DISKUS
1.
NAME OF THE MEDICINAL PRODUCT
Serevent Diskus
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Serevent Diskus is a moulded plastic device containing a foil strip
with regularly spaced
blisters each containing 50 micrograms of salmeterol (as xinafoate).
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Inhalation powder.
4. CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Salmeterol is a selective
β
2
-agonist indicated for reversible airways obstruction in patients
with asthma and chronic obstructive pulmonary disease (COPD).
In asthma (including nocturnal asthma and exercise induced symptoms)
it is indicated for
those treated with inhaled corticosteroids who require a long-acting
beta agonist in
accordance with current treatment guidelines.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Serevent Diskus is not a replacement for inhaled or oral
corticosteroids which should be
continued at the same dose, and not stopped or reduced, when treatment
with Serevent
Diskus is initiated.
Serevent Diskus is for inhalation use only.
Serevent Diskus should be used regularly. The full benefits of
treatment will be apparent
after several doses of the drug.
In asthma
_Adults (including the elderly):_
One inhalation (50 micrograms) twice daily, increasing to
two inhalations (2 x 50 micrograms) twice daily if required.
_Children 4 years and over:_
One inhalation (50 micrograms) twice daily.
The dosage or frequency of administration should only be increased on
medical advice.
_Page 2 of 11 _
There are insufficient clinical data to recommend the use of Serevent
Diskus in children
under the age of four.
In chronic obstructive pulmonary disease
_Adults (including the elderly):_
One inhalation (50 micrograms) twice daily.
_Children:_
Not appropriate.
_Special patient groups:_
There is no need to adjust the dose in patients with impaired renal
function.
Using the Diskus:
The Diskus should be used in a standing or sitting position. The
device is opened and
primed by sliding the lever. The